Concepedia

The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer

Laureen A. Lammers, Ron H.J. Mathijssen, Teun van Gelder, Monique J. Bijl, A-J M de Graan, Caroline Seynaeve, M A van Fessem, E. Berns, Arnold G. Vulto, Ron H. N. van Schaik

British Journal of Cancer · 2010 · 60 citations · 25 references

DOIFull text

Open access

Abstract

CYP2D6 phenotype is an important predictor of treatment outcome in women who are receiving tamoxifen for MBC. Co-administration of CYP2D6 inhibitors worsens treatment outcome of tamoxifen and should therefore be handled with care.

References

25

Patterns of Cancer Incidence, Mortality, and Prevalence Across Five Continents: Defining Priorities to Reduce Cancer Disparities in Different Geographic Regions of the World

Farin Kamangar, Graça M. Dores, William F. Anderson · Journal of Clinical Oncology · 2006 · 3.4K citations

, , +21

Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

Bernard Fisher, Joseph P. Costantino, D. Lawrence Wickerham et al. · JNCI Journal of the National Cancer Institute · 2005 · 1.3K citations

Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot Flashes

Matthew P. Goetz, James M. Rae, Vera J. Suman et al. · Journal of Clinical Oncology · 2005 · 778 citations · Full text

Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

Charles L. Loprinzi, John W. Kugler, Jeff A Sloan et al. · The Lancet · 2000 · 733 citations

, , +6

Assessment of response to therapy in advanced breast cancer.A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland

J.L. Hayward, Paul P. Carbone, Jean-Claude Heuson et al. · Cancer · 1977 · 626 citations · Full text